Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Loeffler

Showing results (231-240 of 329) with videos related to

Pageof 33
Sort By:
BMC Cancer|May 26, 2020
Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort studyKarolin Bucksch, Silke Zachariae, Stefan Aretz, et al.
The Lancet. Oncology|May 2, 2006
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) GroupMichael Pfreundschuh, Lorenz Trümper, Anders Osterborg, et al.
Blood|August 26, 2010
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHLGerman Ott, Marita Ziepert, Wolfram Klapper, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2021
Telomerase reverse transcriptase promoter mutation- and O<sup>6</sup>-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?Dorothee Gramatzki, Jörg Felsberg, Bettina Hentschel, et al.
The Lancet. Oncology|January 30, 2008
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Michael Pfreundschuh, Joerg Schubert, Marita Ziepert, et al.
Leukemia|September 19, 2019
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHLAnnette M Staiger, Michael Altenbuchinger, Marita Ziepert, et al.
Obesity (Silver Spring, Md.)|September 27, 2023
Genetic dissection of serum vaspin highlights its causal role in lipid metabolismJana Breitfeld, Katrin Horn, Diana Le Duc, et al.
Cancer Letters|July 16, 2008
Ten recently identified associations between nsSNPs and colorectal cancer could not be replicated in German familiesBernd Frank, Barbara Burwinkel, Justo Lorenzo Bermejo, et al.
Leukemia & Lymphoma|August 26, 2017
Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYCUlrike Paul, Julia Richter, Christiane Stuhlmann-Laiesz, et al.
International Journal of Cancer|September 1, 2021
Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome and familial colorectal cancer type XKarolin Bucksch, Silke Zachariae, Aysel Ahadova, et al.
Pageof 33

Showing results (231-240 of 329) with videos related to

Sort By:
Pageof 33
BMC Cancer|May 26, 2020
Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort studyKarolin Bucksch, Silke Zachariae, Stefan Aretz, et al.
The Lancet. Oncology|May 2, 2006
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) GroupMichael Pfreundschuh, Lorenz Trümper, Anders Osterborg, et al.
Blood|August 26, 2010
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHLGerman Ott, Marita Ziepert, Wolfram Klapper, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2021
Telomerase reverse transcriptase promoter mutation- and O<sup>6</sup>-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?Dorothee Gramatzki, Jörg Felsberg, Bettina Hentschel, et al.
The Lancet. Oncology|January 30, 2008
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Michael Pfreundschuh, Joerg Schubert, Marita Ziepert, et al.
Leukemia|September 19, 2019
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHLAnnette M Staiger, Michael Altenbuchinger, Marita Ziepert, et al.
Obesity (Silver Spring, Md.)|September 27, 2023
Genetic dissection of serum vaspin highlights its causal role in lipid metabolismJana Breitfeld, Katrin Horn, Diana Le Duc, et al.
Cancer Letters|July 16, 2008
Ten recently identified associations between nsSNPs and colorectal cancer could not be replicated in German familiesBernd Frank, Barbara Burwinkel, Justo Lorenzo Bermejo, et al.
Leukemia & Lymphoma|August 26, 2017
Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYCUlrike Paul, Julia Richter, Christiane Stuhlmann-Laiesz, et al.
International Journal of Cancer|September 1, 2021
Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome and familial colorectal cancer type XKarolin Bucksch, Silke Zachariae, Aysel Ahadova, et al.
Pageof 33